Semiconductor and AI giant Nvidia has expanded its strategic footprint in Israel with the establishment of a new research group named Applied AI Architecture, embedded directly within the global Office of the CTO. Led by Nvidia’s Global CTO Michael Kagan—a co-founder of Mellanox and the highest-ranking Israeli executive reporting directly to CEO Jensen Huang—the group is designed to pivot artificial intelligence from a computational engine into a primary accelerator for long-term scientific and biomedical breakthroughs. The unit is headed by Dr. Nati Daniel, an AI PhD from the Technion with previous executive R&D tenures at Intel, GE, and Huawei, and has initiated recruitment for dozens of senior researchers in Tel Aviv.

Frontier Healthcare: Genomic Foundation Models and the $1B Eli Lilly Venture

Unlike conventional product development units, the Israel-based research team operates under an open-innovation model that combines internal fundamental research with institutional medical collaborations. A core ongoing initiative involves a partnership with Sheba Medical Center and New York’s Mount Sinai Hospital to construct a Genomic Foundation Model (gFM). This AI model is engineered to analyze the 98% of the human genome currently classified as non-coding or under-researched, aiming to unlock novel pathways for disease prevention, early diagnostics, and personalized therapeutics. Concurrently, the group is integrated into Nvidia’s global $1 billion, five-year joint initiative with pharmaceutical giant Eli Lilly to streamline AI-driven drug discovery, alongside its participation in the EU-funded GENMAT consortium focused on advanced material synthesis.

Talent Acquisition and Israel’s Broader Macroeconomic Trajectory

Locating this CTO-level research hub in Israel leverages the country’s dense convergence of clinical data, medical centers, and advanced AI research talent. Expanding Nvidia’s local footprint beyond legacy networking and hardware R&D into life sciences and deep tech reinforces the economic integration between the enterprise and the Israeli market. As Nvidia expands its high-value research operations, the resulting capital expenditure, employment generation, and intellectual property creation are poised to yield positive macroeconomic spillovers across national export figures and fiscal revenues.

Nvidia’s initiative reflects a broader structural evolution across the technology landscape, where the next horizon of value creation depends on deploying foundation models to solve complex biological and material science problems. For Israel, hosting Nvidia’s primary R&D engine for genomic AI and computational biology solidifies its position as a critical node in deep-tech innovation. While this deepens the macroeconomic correlation between the domestic economy and Nvidia’s market performance, it simultaneously embeds the local ecosystem into the long-term infrastructure of global scientific discovery.